- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05687591
Left Atrial Appendage Occlusion With The Amplatzer Amulet Device: The Southeast Asia Observational Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is both retrospective and prospective, multicenter observational study for all patient indicated for LAAO with the Amplatzer Amulet device, involving subjects who had their occluder implanted, been recently implanted or intended to undergo the procedure may be considerd to participate in the study. The sample size is 100 and is based on the estimated number of recruitments from the participating centers. The study duration is 12 months of recruitment plus 1 year follow-up for outcomes. The outcomes are measured based on the objectives of the study:
Primary objective:
To explore on the short-term and long-term (1 year) safety and efficacy of LAA occlusion with the Amplatzer Amulet Device in Southeast Asia population on a real-world basis.
Secondary objective:
To compare the practice of LAA occlusion with Amplatzer Amulet Device in Southeast Asia population with the European registries.
Exploratory objective:
To explore the cost effectiveness of LAA occlusion with the Amplatzer Amulet Device in the Southeast Asia.
Descriptive statistics includes percentage, mean with standard deviation, or median with interquartile range will be reported, whichever appropriate. Categorical variables will be analysed using chi-square test or Fisher's exact test. Continuous variables will be analysed using independent (two variables only) or ANOVA test (more than two variables), or Mann-Whitney test (two variables only) or Kruskal-Wallis test (more than two variables) depending on the nature of underlying distributions. Time dependent outcome data will be analysed using Kaplan-Meier survival analysis.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Sarawak
-
Kuching, Sarawak, Malaysia, 94300
- Sarawak Heart Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- 18 year of age or older
- Documented paroxysmal, persistent, or permanent non-valvular atrial fibrillation
- At high risk of stroke or systemic embolism defined as CHA2DS2-VASc score of more than or equal to 3
- Deemed suitable for LAA occlusion by the treating physician, who might or might not be the investigator
- Able to comply with the required medication regimen post-device implant
- Able and willing to return for required follow-up visits and examinations
Exclusion Criteria:
- With active endocarditis or other infections producing bacteremia
- Where placement of the device would interfere with any intracardiac or intravascular structures
- Reversible cause of AF (i.e. secondary to thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures)
- Hypersensitivity to any portion of the device material or individual components of the Amulet LAA closure device
- Actively enrolled or plans to enroll in a concurrent clinical study in which the active treatment arm may confound the results of this trial
- Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the patient's ability to participate in the clinical trial or to comply with follow up requireemnts, or impact the scientific soundness of the clinical trial results.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Other
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Patients indicated for LAAO with the Amplatzer Amulet
All subjects who are indicated for LAAO with the Amplatzer Amulet are eligible for the study.
|
The Amplatzer Amulet LAAO is a transcatheter, self-expanding device intended for use in preventing thrombus embolization from the left atrial appendage.
The device is constucted from a nitinol mesh and consists of a lobe and a disc connected by a central waist.
Polyester patches are sewn into both the lobe and disc to facilitate occlusion.
The lobe has stabilizing wires to improve device placement and retention.
The device has threaded screw attachments at each end for connection to the delivery and loading cables.
The device has radiopaque markers at each end and at the stabilizing wires that permit visibility during fluoroscopy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Device embolization
Time Frame: 1 year
|
To determine if device embolization occurs (Yes/No).
This is visualized through TOE or CT scan or TOE and CT scan
|
1 year
|
|
Device dislocation and device related thrombus
Time Frame: 1 year
|
To determine if there is any device-associated thrombus occurs after the implantation of the occluder (Presence/Absence).
This is visualized through TOE or CT scan or TOE and CT scan.
|
1 year
|
|
Peri-device leak
Time Frame: 1 year
|
To determine if there is peri-device leak occurs after the implantation of the occluder (Yes/No).
This is visualized through TOE or CT scan or TOE and CT scan.
|
1 year
|
|
Residual interatrial shunt
Time Frame: 1 year
|
To determine if there is residual interatrial shunt occurs after the implantation of the occluder (Yes/No).
This is visualized through TOE or CT scan or TOE and CT scan.
|
1 year
|
|
Mortality
Time Frame: 1 year
|
To determine the mortality at 1 year after LAA occluder implantation
|
1 year
|
|
Ischemic Stroke and TIA
Time Frame: 1 year
|
To determine the rate of ischemic stroke and TIA at 1 year after LAA occluder implantation
|
1 year
|
|
Major adverse bleeding event
Time Frame: 1 year
|
To determine the rate of major adverse bleeding event at 1 year after LAA occluder implantation
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dr. Keng Tat Koh, MBBS, Sarawak Heart Centre
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Amulet-SEA-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Medtronic Cardiac Ablation SolutionsRecruitingParoxysmal Atrial Fibrillation (PAF) | Persistent Atrial Fibrillation | Atrial Fibrillation (AF)Australia, United States, France, Belgium, Switzerland, Czechia
-
Boston Scientific CorporationRecruitingAtrial Fibrillation (AF) | Persistant Atrial FibrillationUnited States, Spain, Belgium, France, Netherlands, Germany, Hong Kong
-
China National Center for Cardiovascular DiseasesRecruitingAtrial Fibrillation Ablation | Atrial Fibrillation (AF) | Radiofrequency Catheter Ablation | Atrial Fibrillation Recurrent | Pulsed Field AblationChina
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
CortexAblacon, Inc.Active, not recruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Medtronic Cardiac Ablation SolutionsNot yet recruitingParoxysmal Atrial Fibrillation (PAF) | Persistent Atrial Fibrillation
-
University Medical Centre LjubljanaEnrolling by invitationPersistent Atrial Fibrillation | Persistent Atrial Fibrillation LongstandingSlovenia
-
Boston Scientific CorporationRecruitingParoxysmal Atrial Fibrillation | Persistent Atrial FibrillationHong Kong, Czechia, Croatia, Taiwan
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
Clinical Trials on Amplatzer Amulet Left Atrial Appendage Occlusion Device
-
R&D CardiologieZonMw: The Netherlands Organisation for Health Research and DevelopmentActive, not recruitingAtrial Fibrillation | Anticoagulants and Bleeding DisordersNetherlands
-
Insel Gruppe AG, University Hospital BernActive, not recruitingLeft Atrial Appendage ClosureBelgium, France, Italy, Switzerland
-
Conformal Medical, IncRecruitingStroke | Atrial FibrillationUnited States, France, Georgia, Uzbekistan, Czechia
-
Abbott Medical DevicesTerminated
-
Abbott Medical DevicesActive, not recruitingStroke | Atrial Fibrillation | BleedingUnited States, France, Spain, Australia, Denmark, Italy, Germany, Canada, Netherlands, Japan, Hong Kong, Switzerland, Lithuania, Czechia, Poland, United Kingdom
-
Kansas City Heart Rhythm Research FoundationKansas City Heart Rhythm InstituteNot yet recruitingStroke | Atrial FibrillationUnited States
-
Abbott Medical DevicesCompletedStrokeUnited States, Denmark, Germany, Australia, Spain, Canada, Czechia, Italy, Netherlands, Portugal, Switzerland
-
Laminar, Inc.Active, not recruitingAtrial FibrillationGeorgia, Paraguay
-
Medtronic CardiovascularTerminatedLeft Atrial Appendage OcclusionUnited States
-
Cardiovascular Center FrankfurtCompletedStroke | Atrial Fibrillation | Bleeding | Leakage of Cardiac DeviceDenmark, United States, Spain, Switzerland, Germany, Poland, United Kingdom